HY-18719 Search Results


endoxifen  (MedChemExpress)
90
MedChemExpress endoxifen
Endoxifen, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/endoxifen/product/MedChemExpress
Average 90 stars, based on 1 article reviews
endoxifen - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
end  (MedChemExpress)
92
MedChemExpress end
<t>Z-endoxifen</t> <t>(END)</t> and 4-Hydroxytamoxifen (4HT) concentrations in 16 participants with breast cancer taking tamoxifen 20 mg daily: ( a ) Distribution of END concentrations in venous blood and in plasma. The means were not significantly different ( P = 0.257); ( b ) Distribution of ratios of plasma to venous blood END concentrations; ( c ) Distribution of 4HT concentrations in venous blood and in plasma. The means were not significantly different ( P = 0.496); ( d ) Distribution of ratios of plasma to venous blood 4HT concentrations. The longer horizontal lines represent means (of concentrations or ratios), and the shorter horizontal lines represent standards of the mean (SEM).
End, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/end/product/MedChemExpress
Average 92 stars, based on 1 article reviews
end - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

Image Search Results


Z-endoxifen (END) and 4-Hydroxytamoxifen (4HT) concentrations in 16 participants with breast cancer taking tamoxifen 20 mg daily: ( a ) Distribution of END concentrations in venous blood and in plasma. The means were not significantly different ( P = 0.257); ( b ) Distribution of ratios of plasma to venous blood END concentrations; ( c ) Distribution of 4HT concentrations in venous blood and in plasma. The means were not significantly different ( P = 0.496); ( d ) Distribution of ratios of plasma to venous blood 4HT concentrations. The longer horizontal lines represent means (of concentrations or ratios), and the shorter horizontal lines represent standards of the mean (SEM).

Journal: Scientific Reports

Article Title: Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer

doi: 10.1038/s41598-022-05443-0

Figure Lengend Snippet: Z-endoxifen (END) and 4-Hydroxytamoxifen (4HT) concentrations in 16 participants with breast cancer taking tamoxifen 20 mg daily: ( a ) Distribution of END concentrations in venous blood and in plasma. The means were not significantly different ( P = 0.257); ( b ) Distribution of ratios of plasma to venous blood END concentrations; ( c ) Distribution of 4HT concentrations in venous blood and in plasma. The means were not significantly different ( P = 0.496); ( d ) Distribution of ratios of plasma to venous blood 4HT concentrations. The longer horizontal lines represent means (of concentrations or ratios), and the shorter horizontal lines represent standards of the mean (SEM).

Article Snippet: END (Z-endoxifen 99.3% E/Z Mixture 50/50, product #D21865, batch #HY-18719A/CS-5098) was obtained from Med Chem Express Europe (Sweden).

Techniques: Clinical Proteomics

Mass spectrometry results demonstrating fragmentation pathways for tamoxifen (TAM), Z-endoxifen (END), and 4-hydroxytamoxifen (4HT), respectively. The graphs show the separate peaks for each analyte and demonstrate that there is no overlap between the peaks of these analytes or of any other TAM metabolites.

Journal: Scientific Reports

Article Title: Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer

doi: 10.1038/s41598-022-05443-0

Figure Lengend Snippet: Mass spectrometry results demonstrating fragmentation pathways for tamoxifen (TAM), Z-endoxifen (END), and 4-hydroxytamoxifen (4HT), respectively. The graphs show the separate peaks for each analyte and demonstrate that there is no overlap between the peaks of these analytes or of any other TAM metabolites.

Article Snippet: END (Z-endoxifen 99.3% E/Z Mixture 50/50, product #D21865, batch #HY-18719A/CS-5098) was obtained from Med Chem Express Europe (Sweden).

Techniques: Mass Spectrometry

Concentration–response calibration curves for ( a ) tamoxifen (TAM), ( b ) Z-endoxifen (END), and ( c ) 4-hydroxytamoxifen (4HT). Calibration curve linearity was r = 0.999 and r 2 = 0.999 for TAM, r = 0.999 and r 2 = 0.997 for END, and r = 0.999 and r 2 = 0.999 for 4HT.

Journal: Scientific Reports

Article Title: Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer

doi: 10.1038/s41598-022-05443-0

Figure Lengend Snippet: Concentration–response calibration curves for ( a ) tamoxifen (TAM), ( b ) Z-endoxifen (END), and ( c ) 4-hydroxytamoxifen (4HT). Calibration curve linearity was r = 0.999 and r 2 = 0.999 for TAM, r = 0.999 and r 2 = 0.997 for END, and r = 0.999 and r 2 = 0.999 for 4HT.

Article Snippet: END (Z-endoxifen 99.3% E/Z Mixture 50/50, product #D21865, batch #HY-18719A/CS-5098) was obtained from Med Chem Express Europe (Sweden).

Techniques: Concentration Assay